Regen Biopharma Inc (RGBP) 0.3650 $RGBP
Regen BioPharma Inc. Announces Small Molecule Drug Discovery Milestones at the American Association for Cancer Research's 2015 Annual Meeting
Marketwired - Thu Apr 09, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today the acceptance of its abstract "Discovery of retinoic acids as low affinity inhibitors of the leukemia stem cell target NR2F6" at the American Association for Cancer Research Annual Meeting taking place April 18-22, 2015 in Philadelphia, Pennsylvania.
Regen BioPharma Inc. to Present Multiple Presentations at the 13th International Symposium on Myelodysplastic Syndromes
Marketwired - Tue Apr 07, 9:22AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that the 13th International Symposium on Myelodysplastic Syndromes has accepted three presentations prepared by Regen BioPharma Inc. The accepted abstracts highlight the work being done in the Company's area of expertise in Aplastic Anemia and Myelodysplastic Syndrome. The link to the conference is http://mds.kenes.com
Regen BioPharma Expands Its Differentiation Therapy of Cancer Stem Cells Platform With Filing of Patent Applications on Silencing of NR2F2
Marketwired - Mon Apr 06, 11:00AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today the expansion of its cancer stem cell intellectual property portfolio to include targeting of the gene NR2F2 (also known as COUP-TFII), a closely related family member to the cancer stem cell gene NR2F6, with the filing of two patent applications. Patent application #14588374 is for Treatment of Myelodysplastic Syndrome by Inhibition of NR2F2 and patent application # 14588373 is for Methods and Compositions for treatment of cancer by inhibition of NR2F2.
Regen BioPharma CEO Discusses Recent Financings, New Laboratory Facilities and Preferred Stock Dividend
Marketwired - Wed Apr 01, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) Chairman & CEO David Koos provided the following update and clarification on recent financings done by the Company, along with new laboratory facilities and preferred stock dividend announcements:
Regen BioPharma Announces Presentation of DiffronC at Cold Spring Harbor Conference on RNA & Oligonucleotide Therapeutics
Marketwired - Tue Mar 31, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today that its abstract entitled "Development of DiffronC gene silencing technology for silencing of the novel leukemia stem cell target NR2F6" was accepted for presentation at the Cold Spring Harbor Conference on RNA & Oligonucleotide Therapeutics, April 8 - 11, 2015.
Regen BioPharma, Inc. Expands Research Capacity With New Laboratory Facilities
Marketwired - Tue Mar 24, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today the acquisition of new laboratory facilities in La Jolla area of San Diego, California. The laboratory space being leased by Regen is located within the Human BioMolecular Research Institute and provides the Company with access to molecular and cellular biology facilities critical to the Company's cancer stem cell research. Experimental studies in the new laboratory have commenced this week with an initial focus on performing pre-clinical experiments whose objective is the advancement of the Company's cancer stem cell and telomere therapeutic pipeline.
Regen Receives Green Light From FDA to Proceed With GLP Safety Study in Support of Its HemaXellerate Investigational New Drug Application
Marketwired - Tue Mar 17, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that it has received final comments and authorization from the FDA to proceed with its GLP Safety Study in support of the company's HemaXellerate Investigational New Drug application (IND) which is on file with the FDA.
Regen BioPharma Acquires Issued Patent and Preclinical Data Package for Targeting Cancer Stem Cell
Marketwired - Tue Mar 10, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today successful closing of a transaction resulting in acquisition of issued US patent #8,263,571, and associated preclinical data package. The intellectual property covers specific therapeutic agents that gene silence CTCFL. CTCFL, otherwise known as Brother of the Regulator of Imprinted Sites (BORIS) is a gene that is critical for cancer stem cells to survive, in part by inducing expression of telomerase, a protein that creates cellular immortality(1).
Penny Stocks Report for Titan Pharmaceuticals, American Green, Banro, Globalstar, IFAN Financial, and Regen BioPharma
PR Newswire - Tue Mar 03, 7:45AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Titan Pharmaceuticals (OTCBB:TTNP), American Green (OTCMKTS:ERBB), Banro (NYSEMKT:BAA), Globalstar (NYSEMKT:GSAT), IFAN Financial (OTCBB:IFAN), and Regen BioPharma (OTCBB:RGBP).
BAA: 0.22 (unch), GSAT: 3.00 (+0.02)
Regen BioPharma Inc. Files Patent Application for Treatment of Myelodysplastic Syndrome Utilizing Gene Silencing Therapy
Marketwired - Tue Mar 03, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today the filing of patent application # 14,572/574 covering methods, compositions, and protocols for the treatment of myelodysplastic syndrome by gene silencing using Regen's proprietary siRNA therapeutic sequences platform.
Regen BioPharma, Inc. Expands Management Team With the Addition of New CFO Todd Caven
Marketwired - Tue Feb 17, 7:31AM CST
Regen BioPharma Inc. (OTC PINK: RGBP) announced that it has appointed Todd Caven to serve as the company's Chief Financial Officer. Mr. Caven is the cofounder of Saguaro Capital Partners, an Arizona based company that raises growth capital for medical device and technology companies throughout the United States., and Rock Ridge Enterprises LLC, a Minnesota-based Private Equity firm. Mr. Caven earned an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University.
Regen BioPharma, Inc. Provides Update on Company's Progress and Areas of Specialization for 2015
Marketwired - Wed Jan 14, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) provided the following update on the Company's direction for 2015:
Regen BioPharma Inc. Identifies Second Generation Gene Silencing Candidates for Blocking Cancer Stem Cell Gene Target
Marketwired - Thu Jan 08, 7:31AM CST
Regen BioPharma Inc. (OTCBB: RGBP) announced today the discovery and demonstration of in vitro efficacy of a second generation of gene silencing drug candidates with specificity to the cancer stem cell gene NR2F6.
Regen BioPharma Presented Novel Therapeutic Target for Leukemia and Myelodysplastic Syndrome at the American Society of Hematology Annual Meeting
Marketwired - Thu Dec 11, 7:57AM CST
Regen BioPharma Inc. (OTC PINK: RGBP) announced today it presented data demonstrating NR2F6, a new drug target, is essential in development and maintenance of leukemia and myelodysplastic syndrome at the American Society of Hematology Annual Meeting. This new drug target was identified by the Company's senior research consultant, Dr. Christine Ichim. A drug target is a gene involved in a disease which researchers aim to inhibit its function in order to treat the disease. Regen recently acquired intellectual property generated at the University of Toronto for inhibiting NR2F6.
Regen BioPharma Scheduled to Make Presentation at American Society for Hematology's 56th Annual Meeting in San Francisco December 6th - 9th
Marketwired - Mon Dec 01, 7:30AM CST
Regen BioPharma (OTCBB: RGBP) announced today acceptance by the American Society for Hematology of a presentation by Christine Ichim, PhD, senior scientific research consultant to Regen BioPharma, at its annual meeting entitled "NR2F6 (EAR-2) Is a Novel Leukemia Oncogene Whose Cellular Function Is to Regulate Terminal Differentiation of Erythrocytes at the Proerythroblast Stage." The work will be presented on Saturday December 6, 2014 at the West Building, Level 1 in the Moscone Center, San Francisco at 5:30 PM.
Regen BioPharma Acquires University of Toronto Cancer Stem Cell Intellectual Property
Marketwired - Tue Nov 25, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) announced today acquisition of patent application # US 13/652,395 with a priority date of November 2008 which covers a novel gene target essential for the survival of cancer stem cells. Inventors of the intellectual property on which this patent application was filed are University of Toronto Hematologist Dr. Richard Wells and Dr. Christine Ichim, Senior Research Consultant for Regen BioPharma.
Regen Bio's dCellVax IND on go
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 11:47AM CST
FDA Issues IND Number for Regen BioPharma's dCellVax Therapeutic Application, a Proposed Treatment for Breast Cancer
Marketwired - Tue Nov 04, 7:31AM CST
Regen BioPharma, Inc. (OTCBB: RGBP) announced today issuance of IND (Investigational New Drug Application) number 16200 from the FDA for a proposed Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell immunotherapy for treating breast cancer.
Regen BioPharma's Chief Scientific Officer Examines Potential Role of Immunotherapeutic Treatment for Ebola in Conjunction With Other Current Therapies
Marketwired - Tue Oct 28, 8:05AM CDT
Regen BioPharma Inc.'s (OTCBB: RGBP) Chief Scientific Officer Dr. Thomas Ichim stated today that The Company is currently identifying potential immunotherapeutic treatments that might have value in treating some of the effects of Ebola in conjunction with other treatments. The goal of using immunotherapy in mitigating some of the side effects of Ebola is to jump start the body's own immune system to identify and fight off these potentially fatal conditions.
Regen BioPharma Inc. Announces Small Molecule Drug Discovery Milestones at the American Association for Cancer Research's 2015 Annual Meeting
Marketwired - Thu Apr 09, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today the acceptance of its abstract "Discovery of retinoic acids as low affinity inhibitors of the leukemia stem cell target NR2F6" at the American Association for Cancer Research Annual Meeting taking place April 18-22, 2015 in Philadelphia, Pennsylvania.
Regen BioPharma Inc. to Present Multiple Presentations at the 13th International Symposium on Myelodysplastic Syndromes
Marketwired - Tue Apr 07, 9:22AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that the 13th International Symposium on Myelodysplastic Syndromes has accepted three presentations prepared by Regen BioPharma Inc. The accepted abstracts highlight the work being done in the Company's area of expertise in Aplastic Anemia and Myelodysplastic Syndrome. The link to the conference is http://mds.kenes.com
Regen BioPharma Expands Its Differentiation Therapy of Cancer Stem Cells Platform With Filing of Patent Applications on Silencing of NR2F2
Marketwired - Mon Apr 06, 11:00AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today the expansion of its cancer stem cell intellectual property portfolio to include targeting of the gene NR2F2 (also known as COUP-TFII), a closely related family member to the cancer stem cell gene NR2F6, with the filing of two patent applications. Patent application #14588374 is for Treatment of Myelodysplastic Syndrome by Inhibition of NR2F2 and patent application # 14588373 is for Methods and Compositions for treatment of cancer by inhibition of NR2F2.
Regen BioPharma CEO Discusses Recent Financings, New Laboratory Facilities and Preferred Stock Dividend
Marketwired - Wed Apr 01, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) Chairman & CEO David Koos provided the following update and clarification on recent financings done by the Company, along with new laboratory facilities and preferred stock dividend announcements:
Regen BioPharma Announces Presentation of DiffronC at Cold Spring Harbor Conference on RNA & Oligonucleotide Therapeutics
Marketwired - Tue Mar 31, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today that its abstract entitled "Development of DiffronC gene silencing technology for silencing of the novel leukemia stem cell target NR2F6" was accepted for presentation at the Cold Spring Harbor Conference on RNA & Oligonucleotide Therapeutics, April 8 - 11, 2015.
Regen BioPharma, Inc. Expands Research Capacity With New Laboratory Facilities
Marketwired - Tue Mar 24, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today the acquisition of new laboratory facilities in La Jolla area of San Diego, California. The laboratory space being leased by Regen is located within the Human BioMolecular Research Institute and provides the Company with access to molecular and cellular biology facilities critical to the Company's cancer stem cell research. Experimental studies in the new laboratory have commenced this week with an initial focus on performing pre-clinical experiments whose objective is the advancement of the Company's cancer stem cell and telomere therapeutic pipeline.
Regen Receives Green Light From FDA to Proceed With GLP Safety Study in Support of Its HemaXellerate Investigational New Drug Application
Marketwired - Tue Mar 17, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that it has received final comments and authorization from the FDA to proceed with its GLP Safety Study in support of the company's HemaXellerate Investigational New Drug application (IND) which is on file with the FDA.
Regen BioPharma Acquires Issued Patent and Preclinical Data Package for Targeting Cancer Stem Cell
Marketwired - Tue Mar 10, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today successful closing of a transaction resulting in acquisition of issued US patent #8,263,571, and associated preclinical data package. The intellectual property covers specific therapeutic agents that gene silence CTCFL. CTCFL, otherwise known as Brother of the Regulator of Imprinted Sites (BORIS) is a gene that is critical for cancer stem cells to survive, in part by inducing expression of telomerase, a protein that creates cellular immortality(1).
Penny Stocks Report for Titan Pharmaceuticals, American Green, Banro, Globalstar, IFAN Financial, and Regen BioPharma
PR Newswire - Tue Mar 03, 7:45AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Titan Pharmaceuticals (OTCBB:TTNP), American Green (OTCMKTS:ERBB), Banro (NYSEMKT:BAA), Globalstar (NYSEMKT:GSAT), IFAN Financial (OTCBB:IFAN), and Regen BioPharma (OTCBB:RGBP).
BAA: 0.22 (unch), GSAT: 3.00 (+0.02)
Regen BioPharma Inc. Files Patent Application for Treatment of Myelodysplastic Syndrome Utilizing Gene Silencing Therapy
Marketwired - Tue Mar 03, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today the filing of patent application # 14,572/574 covering methods, compositions, and protocols for the treatment of myelodysplastic syndrome by gene silencing using Regen's proprietary siRNA therapeutic sequences platform.
Regen BioPharma, Inc. Expands Management Team With the Addition of New CFO Todd Caven
Marketwired - Tue Feb 17, 7:31AM CST
Regen BioPharma Inc. (OTC PINK: RGBP) announced that it has appointed Todd Caven to serve as the company's Chief Financial Officer. Mr. Caven is the cofounder of Saguaro Capital Partners, an Arizona based company that raises growth capital for medical device and technology companies throughout the United States., and Rock Ridge Enterprises LLC, a Minnesota-based Private Equity firm. Mr. Caven earned an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University.
Regen BioPharma, Inc. Provides Update on Company's Progress and Areas of Specialization for 2015
Marketwired - Wed Jan 14, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) provided the following update on the Company's direction for 2015:
Regen BioPharma Inc. Identifies Second Generation Gene Silencing Candidates for Blocking Cancer Stem Cell Gene Target
Marketwired - Thu Jan 08, 7:31AM CST
Regen BioPharma Inc. (OTCBB: RGBP) announced today the discovery and demonstration of in vitro efficacy of a second generation of gene silencing drug candidates with specificity to the cancer stem cell gene NR2F6.
Regen BioPharma Presented Novel Therapeutic Target for Leukemia and Myelodysplastic Syndrome at the American Society of Hematology Annual Meeting
Marketwired - Thu Dec 11, 7:57AM CST
Regen BioPharma Inc. (OTC PINK: RGBP) announced today it presented data demonstrating NR2F6, a new drug target, is essential in development and maintenance of leukemia and myelodysplastic syndrome at the American Society of Hematology Annual Meeting. This new drug target was identified by the Company's senior research consultant, Dr. Christine Ichim. A drug target is a gene involved in a disease which researchers aim to inhibit its function in order to treat the disease. Regen recently acquired intellectual property generated at the University of Toronto for inhibiting NR2F6.
Regen BioPharma Scheduled to Make Presentation at American Society for Hematology's 56th Annual Meeting in San Francisco December 6th - 9th
Marketwired - Mon Dec 01, 7:30AM CST
Regen BioPharma (OTCBB: RGBP) announced today acceptance by the American Society for Hematology of a presentation by Christine Ichim, PhD, senior scientific research consultant to Regen BioPharma, at its annual meeting entitled "NR2F6 (EAR-2) Is a Novel Leukemia Oncogene Whose Cellular Function Is to Regulate Terminal Differentiation of Erythrocytes at the Proerythroblast Stage." The work will be presented on Saturday December 6, 2014 at the West Building, Level 1 in the Moscone Center, San Francisco at 5:30 PM.
Regen BioPharma Acquires University of Toronto Cancer Stem Cell Intellectual Property
Marketwired - Tue Nov 25, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) announced today acquisition of patent application # US 13/652,395 with a priority date of November 2008 which covers a novel gene target essential for the survival of cancer stem cells. Inventors of the intellectual property on which this patent application was filed are University of Toronto Hematologist Dr. Richard Wells and Dr. Christine Ichim, Senior Research Consultant for Regen BioPharma.
Regen Bio's dCellVax IND on go
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 11:47AM CST
FDA Issues IND Number for Regen BioPharma's dCellVax Therapeutic Application, a Proposed Treatment for Breast Cancer
Marketwired - Tue Nov 04, 7:31AM CST
Regen BioPharma, Inc. (OTCBB: RGBP) announced today issuance of IND (Investigational New Drug Application) number 16200 from the FDA for a proposed Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell immunotherapy for treating breast cancer.
Regen BioPharma's Chief Scientific Officer Examines Potential Role of Immunotherapeutic Treatment for Ebola in Conjunction With Other Current Therapies
Marketwired - Tue Oct 28, 8:05AM CDT
Regen BioPharma Inc.'s (OTCBB: RGBP) Chief Scientific Officer Dr. Thomas Ichim stated today that The Company is currently identifying potential immunotherapeutic treatments that might have value in treating some of the effects of Ebola in conjunction with other treatments. The goal of using immunotherapy in mitigating some of the side effects of Ebola is to jump start the body's own immune system to identify and fight off these potentially fatal conditions.
